CureDuchenne Hosts Conversation with Pfizer to Discuss Opening of First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif., May 16, 2022 /PRNewswire/ — CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy (DMD), today released a webinar on the upcoming opening of U.S. trial sites for Pfizer’s CIFFREO trial, a phase 3 study in…